Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| NutriLeads B.V. (Wageningen, The Netherlands) | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The aim of this study is to determine, quantify and understand the potential prebiotic and anti-inflammatory effects of the pecticpolysaccharide rhamnogalacturonan I (RG-I). The effects of these dietary fibre fractions on barrier function will also be investigated.
The dietary fibre fractions from RG-I will be tested first for their prebiotic potential. Batch culture fermentation systems containing basal growth medium will be inoculated with faecal homogenates obtained from different time points (Task I) and will be used for analyzing microbiota composition and microbiota-associated metabolites. Subsequently, the collection of colon biopsies through sigmoidoscopy procedure of the same subjects will take place and the collected biopsies will be mounted in Ussing Chambers. Supernatants collected from Task I will be added to the mucosal side of the biopsy together with a stressor and two permeability markers, in order to investigate the effects of the fibre fractions on both paracellular and transcellular permeability.Throughout the study subjects will complete questionnaires related to their gastrointestinal health and dietary habits
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Gut barrier function treatments | Experimental | Stressor, fibre, combination of treatments. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fermented product of carrot derived rhamnogalacturonan I | Other | Stimulation of human colonic biopsies with the fermented product of carrot derived rhamnogalacturonan I |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline of barrier function after 90 minutes of ex vivo stimulation of the colonic biopsies. | Barrier function will be evaluated with the use of markers related to paracellular and transcellular permeability, through immunofluoresence and ELISA tecnhique. | Barrier function will be measured at baseline and after 90 minutes of ex vivo stimulation of the colonic biopsies. |
| Change from baseline to the effect on the intestinal microbial populations and their metabolic products [i.e. Short-Chain Fatty Acids (SCFA)] (prebiotic effect) by the end of the in vitro fermentation process. | Microbial populations will be quantified with 16SRNA sequencing and quantitative Polymerase Chain Reaction (PCR). SCFAs will be quantified with Gas chromatography. | The levels of microbial populations and their metabolic products will be measured at baseline and after 6 hours of in vitro fermentation procedure. |
| Measure | Description | Time Frame |
|---|---|---|
| Effect of RG-I fractions on immune system reinforcement in the end of the ex vivo stimulation of the colonic biopsies. | Selected pro- and anti- inflammatory cytokines levels will be measured on the colonic biopsies tissues by ELISA techniques. | Immune system reinforcement will be evaluated after 90 minutes of ex vivo stimulation of the colonic biopsies. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert Brummer, Professor | Örebro University, School of Medical Sciences, Sweden | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Campus USÖ | Örebro | 703 62 | Sweden |
Not provided
| Label | URL |
|---|---|
| Research center website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jun 11, 2022 | Jun 11, 2022 | Prot_SAP_000.pdf |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Gastrointestinal health status prior to the initiation of the study. | Gastrointestinal health will be evaluated once with the use of a 1-day questionnaire consisting of 13 items concerning satiety, abdominal pain, diarrhoea, constipation and bloating.The intensity of each parameter will be assessed on a scale of 0-7, where '0' represents absence of symptoms and '7' severe symptoms. | Gastrointestinal health will be measured at baseline prior to the initiation of the study as background information. |
| Dietary intake prior to the initiation of the study. | Dietary intake will be evaluated with the use of 3-days diet intake records. | Dietary intake will be measured at baseline prior to the initiation of the study as background information. |
| Dietary habits prior to the initiation of the study. | Dietary habits will be evaluated with the use of food frequency questionnaire (FFQ). | Dietary habits will be measured at baseline prior to the initiation of the study as background information. |